-
JAMA
US Preventive Services Task Force
Modeling Study
April 30, 2024
Amy聽Trentham-Dietz,听笔丑顿, MS; Christina Hunter聽Chapman,聽MD, MS; Jinani聽Jayasekera,听笔丑顿, MS; Kathryn P.听Lowry,聽MD; Brandy M.听Heckman-Stoddard,听笔丑顿, MPH; John M.听Hampton,聽MS; Jennifer L.听Caswell-Jin,聽MD; Ronald E.听Gangnon,听笔丑顿; Ying聽Lu,听笔丑顿, MS; Hui聽Huang,聽MS; Sarah聽Stein,听笔丑顿; Liyang聽Sun,聽MS; Eugenio J.听Gil Quessep,聽MS; Yuanliang聽Yang,聽MS; Yifan聽Lu,聽BASc; Juhee聽Song,听笔丑顿; Diego F.听Mu帽oz,听笔丑顿; Yisheng聽Li,听笔丑顿, MS; Allison W.听Kurian,聽MD, MSc; Karla聽Kerlikowske,聽MD; Ellen S.听O鈥橫eara,听笔丑顿; Brian L.听Sprague,听笔丑顿; Anna N. A.听Tosteson,聽ScD; Eric J.听Feuer,听笔丑顿; Donald聽Berry,听笔丑顿; Sylvia K.听Plevritis,听笔丑顿; Xuelin聽Huang,听笔丑顿; Harry J.听de Koning,聽MD, PhD; Nicolien T.听van Ravesteyn,听笔丑顿; Sandra J.听Lee,聽ScD; Oguzhan聽Alagoz,听笔丑顿, MS; Clyde B.听Schechter,聽MD, MA; Natasha K.听Stout,听笔丑顿; Diana L.听Miglioretti,听笔丑顿, ScM; Jeanne S.听Mandelblatt,聽MD, MPH
free access
is active quiz
has multimedia
online first
JAMA. 2024; 10.1001/jama.2023.24766
This modeling study uses Cancer Intervention and Surveillance Modeling Network models and national data on breast cancer incidence, mammography performance, treatment effects, and other-cause mortality in US women without previous cancer diagnoses to estimate outcomes of various mammography screening strategies.
-
JAMA
Comment & Response
April 25, 2024
Jennifer L.听Caswell-Jin,聽MD; Allison W.听Kurian,聽MD, MSc; Sylvia K.听Plevritis,听笔丑顿
JAMA. 2024; 331(19):1679-1680. 10.1001/jama.2024.5482
-
JAMA
Original Investigation
January 16, 2024
Jennifer L.听Caswell-Jin,聽MD; Liyang P.听Sun,聽MSc; Diego聽Munoz,听笔丑顿; Ying聽Lu,听笔丑顿; Yisheng聽Li,听笔丑顿; Hui聽Huang,聽MS; John M.听Hampton,聽MSc; Juhee聽Song,听笔丑顿; Jinani聽Jayasekera,听笔丑顿; Clyde聽Schechter,聽MD, MA; Oguzhan聽Alagoz,听笔丑顿; Natasha K.听Stout,听笔丑顿; Amy聽Trentham-Dietz,听笔丑顿; Sandra J.听Lee,聽ScD; Xuelin聽Huang,听笔丑顿; Jeanne S.听Mandelblatt,聽MD, MPH; Donald A.听Berry,听笔丑顿; Allison W.听Kurian,聽MD, MSc; Sylvia K.听Plevritis,听笔丑顿
is active quiz
JAMA. 2024; 331(3):233-241. 10.1001/jama.2023.25881
This simulation study estimates the association of breast cancer screening, treatment of stage I-III breast cancer, and treatment of metastatic breast cancer on changes in mortality due to breast cancer in US women for the period 1975-2019.
-
JAMA Oncology
Original Investigation
October 21, 2021
Iakovos聽Toumazis,听笔丑顿; Koen聽de Nijs,聽MSc; Pianpian聽Cao,聽MPH; Mehrad聽Bastani,听笔丑顿; Vidit聽Munshi,听笔丑顿; Kevin聽ten Haaf,听笔丑顿; Jihyoun聽Jeon,听笔丑顿; G. Scott聽Gazelle,聽MD, MPH, PhD; Eric J.听Feuer,听笔丑顿; Harry J.听de Koning,聽MD; Rafael聽Meza,听笔丑顿; Chung Yin聽Kong,听笔丑顿; Summer S.听Han,听笔丑顿; Sylvia K.听Plevritis,听笔丑顿
free access
JAMA Oncol. 2021; 7(12):1833-1842. 10.1001/jamaoncol.2021.4942
This economic evaluation assessed the cost-effectiveness of the 2021 US Preventive Services Task Force recommendation for lung cancer screening compared with the 2013 recommendation and alternative screening strategies.
-
JAMA
US Preventive Services Task Force
Modeling Study
March 9, 2021
Rafael聽Meza,听笔丑顿; Jihyoun聽Jeon,听笔丑顿; Iakovos聽Toumazis,听笔丑顿; Kevin聽ten Haaf,听笔丑顿; Pianpian聽Cao,聽MPH; Mehrad聽Bastani,听笔丑顿; Summer S.听Han,听笔丑顿; Erik F.听Blom,聽MD, PhD; Daniel E.听Jonas,聽MD, MPH; Eric J.听Feuer,听笔丑顿; Sylvia K.听Plevritis,听笔丑顿; Harry J.听de Koning,聽MD, PhD; Chung Yin聽Kong,听笔丑顿
free access
has multimedia
JAMA. 2021; 325(10):988-997. 10.1001/jama.2021.1077
This simluation study models the benefits and harms associated with low-dose computed tomography (LDCT) screening for lung cancer based on a range of starting and stopping ages, screening frequencies, cumulative pack-years, and years since quitting smoking.
-
JAMA
Comment & Response
June 12, 2018
Sylvia K.听Plevritis,听笔丑顿; Donald A.听Berry,听笔丑顿; Jeanne S.听Mandelblatt,聽MD, MPH
JAMA. 2018; 319(22):2336-2336. 10.1001/jama.2018.4261
-
JAMA
Original Investigation
January 9, 2018
Sylvia K.听Plevritis,听笔丑顿; Diego聽Munoz,聽MS, PhD; Allison W.听Kurian,聽MD, MS; Natasha K.听Stout,听笔丑顿; Oguzhan聽Alagoz,听笔丑顿; Aimee M.听Near,聽MPH; Sandra J.听Lee,聽ScD; Jeroen J.听van den Broek,聽MS; Xuelin聽Huang,听笔丑顿; Clyde B.听Schechter,聽MA, MD; Brian L.听Sprague,听笔丑顿; Juhee聽Song,听笔丑顿; Harry J.听de Koning,聽MD, PhD; Amy聽Trentham-Dietz,聽MS, PhD; Nicolien T.听van Ravesteyn,听笔丑顿; Ronald聽Gangnon,听笔丑顿; Young聽Chandler,聽MS, MPH, DrPH; Yisheng聽Li,听笔丑顿; Cong聽Xu,听笔丑顿; Mehmet Ali聽Ergun,听笔丑顿; Hui聽Huang,聽MS; Donald A.听Berry,听笔丑顿; Jeanne S.听Mandelblatt,听笔丑顿
free access
JAMA. 2018; 319(2):154-164. 10.1001/jama.2017.19130
This simulation study estimates reductions in breast cancer mortality associated with screening and treatment by estrogen-receptor and human epidermal growth factor receptor 2 (ERBB2) status.
-
JAMA
Original Contribution
December 22, 2010
Andrew J. Gentles, PhD; Sylvia K. Plevritis, PhD; Ravindra Majeti, MD, PhD; Ash A. Alizadeh, MD, PhD
free access
JAMA. 2010; 304(24):2706-2715. 10.1001/jama.2010.1862
-
JAMA
Letters
December 13, 2006
Sylvia K. Plevritis, PhD; Debra M. Ikeda, MD; Alan M. Garber, MD, PhD
JAMA. 2006; 296(22):2681-2682. 10.1001/jama.296.22.2682
-
JAMA
Original Contribution
May 24, 2006
Sylvia K. Plevritis, PhD; Allison W. Kurian, MD; Bronislava M. Sigal, PhD; Bruce L. Daniel, MD; Debra M. Ikeda, MD; Frank E. Stockdale, MD, PhD; Alan M. Garber, MD, PhD
free access
JAMA. 2006; 295(20):2374-2384. 10.1001/jama.295.20.2374